Literature DB >> 17543852

Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys.

Mark A Young1, Ashok Malavalli, Nancy Winslow, Kim D Vandegriff, Robert M Winslow.   

Abstract

Maleimide-polyethylene glycol-modified (MalPEG) hemoglobin, 4.3 g/dL (MP4; Hemospan), is a hemoglobin-based oxygen carrier consisting of human hemoglobin (Hb) modified with maleimide polyethylene glycol. This study evaluates the potential toxicity and hemodynamic actions of a single dose of MP4 administered by exchange transfusion to rhesus monkeys. Monkeys were administered MP4 (21 mL/kg, or approximately 30% of estimated blood volume) or an equivalent volume of lactated Ringer's solution (LR). In the toxicity study, blood samples were obtained predose and 3, 7, and 13 days after dosing for clinical chemistry and hematology. Animals were euthanized for complete necropsy and histopathology on day 3 or day 13. A separate group of animals was used for evaluation of arterial pressure, core temperature, and electrocardiogram, by telemetry, for 7 days after dosing with MP4. The results demonstrate no significant toxicity, with only modest, transient elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) on day 3. Mild anemia caused by hemodilution was observed at each time point in both groups, but to a slightly greater degree in the MP4-treated animals. Histologic observations included foamy or vacuolated macrophages in the spleen and marrow of the sternum, rib, and femur, representing the accumulation of test article or a metabolite. In the telemetry study, no changes occurred in arterial pressure, heart rate, or electrocardiogram attributable to administration of MP4 at any time for 7 days after administration. These results demonstrate that MP4 is safe and is without hemodynamic effects when administered as an exchange transfusion of 30% of estimated blood volume.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543852     DOI: 10.1016/j.trsl.2006.09.007

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  9 in total

Review 1.  Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions.

Authors:  Andrea Mozzarelli; Luca Ronda; Serena Faggiano; Stefano Bettati; Stefano Bruno
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

2.  Early treatment of transient focal cerebral ischemia with bovine PEGylated carboxy hemoglobin transfusion.

Authors:  Judith A Klaus; Kathleen K Kibler; Abraham Abuchowski; Raymond C Koehler
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2010-10

3.  Modulation of perfusion and oxygenation by red blood cell oxygen affinity during acute anemia.

Authors:  Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-20       Impact factor: 6.914

Review 4.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

5.  PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.

Authors:  Reinhard Reuss
Journal:  Biologics       Date:  2013-05-29

Review 6.  Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers.

Authors:  Kazuaki Taguchi; Keishi Yamasaki; Toru Maruyama; Masaki Otagiri
Journal:  J Funct Biomater       Date:  2017-03-18

7.  IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.

Authors:  Wenwen Bi; Wei Xu; Liang Cheng; Jing Xue; Qian Wang; Fei Yu; Shuai Xia; Qi Wang; Guangming Li; Chuan Qin; Lu Lu; Lishan Su; Shibo Jiang
Journal:  PLoS Pathog       Date:  2019-12-05       Impact factor: 6.823

8.  Effects of maleimide-polyethylene glycol-modified human hemoglobin (MP4) on tissue necrosis in SKH1-hr hairless mice.

Authors:  Ole Goertz; M H Kirschner; H Lilienfein; P Babilas; H U Steinau; C Andree; A Daigeler; A Stachon; H Homann; S Langer
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

Review 9.  Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Eleonora Cocco; Maria Giovanna Marrosu
Journal:  Ther Clin Risk Manag       Date:  2015-05-08       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.